Document Detail


Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception.
MedLine Citation:
PMID:  18284649     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: One of the most frequently asked questions during consultation with those affected by inflammatory bowel disease is what are its effects on pregnancy, and how the treatment will impact on conception and pregnancy outcomes.
AIM: To review available data regarding the safety of biological therapies during pregnancy, primarily in woman with inflammatory bowel disease.
METHODS: A Medline search was performed and available original research and review articles relating to the use of biological (antitumour necrosis factor-alpha) therapies in inflammatory bowel disease were reviewed. Where information regarding the use of a drug in inflammatory bowel disease during pregnancy was limited, articles referring to its use for other indications, such as rheumatoid arthritis, were reviewed.
CONCLUSIONS: Based on available data, biological therapies appear to be safe in pregnancy. Most studies looking at the effects of any one medication on pregnancy in inflammatory bowel disease are confounded by the fact that most patients are on multiple medications and have varying levels of disease activity. Stopping therapy in the third trimester should be considered. Large registries with longer follow-up periods will be necessary before firm conclusions about the safety of antitumour necrosis factor-alpha therapies during conception and pregnancy can be drawn.
Authors:
S O'Donnell; C O'Morain
Related Documents :
19839149 - Maternal deaths due to liver disease in malaysia.
18625819 - Effects and treatment of inflammatory bowel disease during pregnancy.
1065739 - Gingivitis and periodontal disease in pregnancy.
1622959 - Oral carcinoma in pregnancy.
9031379 - Scleroderma and pregnancy.
19818219 - Psoriasis in pregnancy: a review of most important literature data.
22985739 - Environmental exposure to arsenic and cadmium during pregnancy and fetal size: a longit...
11056149 - Three-dimensional qualitative sonographic evaluation of fetal soft tissue.
25024139 - Epigenetic mechanisms regulate placental c-myc and htert in normal and pathological pre...
Publication Detail:
Type:  Case Reports; Journal Article; Review     Date:  2008-02-14
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  27     ISSN:  1365-2036     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-04-17     Completed Date:  2008-06-11     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  885-94     Citation Subset:  IM    
Affiliation:
Department of Gastroenterology, AMNCH/Trinity College Dublin, Dublin, Ireland. odonnes2@tcd.ie
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Female
Humans
Infant, Newborn
Infertility, Male / chemically induced
Inflammatory Bowel Diseases / drug therapy*
Male
Preconception Care
Pregnancy
Pregnancy Complications / drug therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/infliximab; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentr...
Next Document:  Systematic review: prevention of travellers' diarrhoea.